Trials / Recruiting
RecruitingNCT07220564
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Peroral Doses of Inno8 in People With Haemophilia A
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NNC0442-0344 A | NNC0442-0344 A will be administered orally. |
Timeline
- Start date
- 2025-10-23
- Primary completion
- 2026-12-21
- Completion
- 2026-12-21
- First posted
- 2025-10-24
- Last updated
- 2026-03-27
Locations
22 sites across 7 countries: United States, Austria, Germany, Italy, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07220564. Inclusion in this directory is not an endorsement.